Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISM5939 in Advanced and/or Metastatic Solid Tumors
NCT06724042Phase 1Not yet recruiting
- Sponsor
- Insilico Medicine
- Start
- Dec 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of ISM5939 in solid tumor (3 arms), sponsored by Insilico Medicine. Primary endpoints: Dose-limiting toxicities at 21 days, Adverse events at 36 months and 1 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
ISM5939
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06724042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06724042.